Understanding and predicting brain penetration for CNS-targeted drugs
There are numerous strategies available incorporating in silico, in vitro and in vivo tools for optimising brain exposure for CNS-target drugs.
What do you think are the pros and cons of each strategy? At the Romark Medicinal Chemistry Symposium that was held recently in Liverpool, our Director of DMPK, Tim Schulz-Utermoehl, provided an overview of this area.
Check out the slides following the link below:
Why don’t you let us know your thoughts!